Abstract

Despite the use of autologous hematopoietic cell transplantation (AHCT) in treatment of multiple myeloma (MM) for almost 40 years and its persistence as standard-of-care in transplant-eligible patients with MM even after the advent of novel agents, AHCT remains underutilized especially in racial and ethnic minority populations.